Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Review

Meta-analysis of benzodiazepine use in the treatment of insomnia

Anne M. Holbrook, Renée Crowther, Ann Lotter, Chiachen Cheng and Derek King
CMAJ January 25, 2000 162 (2) 225-233;
Anne M. Holbrook
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renée Crowther
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann Lotter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiachen Cheng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek King
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Abstract

Objective: To systematically review the benefits and risks associated with the use of benzodiazepines to treat insomnia in adults.

Data sources: MEDLINE and the Cochrane Controlled Trials Registry were searched for English-language articles published from 1966 to December 1998 that described randomized controlled trials of benzodiazepines for the treatment of insomnia. Key words included "benzodiazepines" (exploded), "randomized controlled trial" and "insomnia." Bibliographies of relevant articles were reviewed for additional studies and manufacturers of benzodiazepines were asked to submit additional randomized controlled trial reports not in the literature.

Study selection: Articles were considered for the meta-analysis if they were randomized controlled trials involving patients with insomnia and compared a benzodiazepine with placebo or another active agent. Of the 89 trials originally identified, 45 met our criteria, representing a total of 2672 patients.

Data extraction: Data were extracted regarding the participants, the setting, details of the intervention, the outcomes (including adverse effects) and the methodologic quality of the studies.

Data synthesis: The meta-analyses of sleep records indicated that, when compared with placebo, benzodiazepines decreased sleep latency by 4.2 minutes (non-significant; 95% confidence interval [CI] −0.7 to 9.2) and significantly increased total sleep duration by 61.8 minutes (95% CI 37.4 to 86.2). Patient-reported outcomes were more optimistic for sleep latency; those randomized to benzodiazepine treatment estimated a sleep latency decrease of 14.3 minutes (95% CI 10.6 to 18.0). Although more patients receiving benzodiazepine treatment reported adverse effects, especially daytime drowsiness and dizziness or light-headedness (common odds ratio 1.8, 95% CI 1.4 to 2.4), dropout rates for the benzodiazepine and placebo groups were similar. Cognitive function decline including memory impairment was reported in several of the studies. Zopiclone was not found to be superior to benzodiazepines on any of the outcome measures examined.

Interpretation: The use of benzodiazepines in the treatment of insomnia is associated with an increase in sleep duration, but this is countered by a number of adverse effects. Additional studies evaluating the efficacy of nonpharmacological interventions would be valuable.

View Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 162, Issue 2
25 Jan 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Meta-analysis of benzodiazepine use in the treatment of insomnia
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Meta-analysis of benzodiazepine use in the treatment of insomnia
Anne M. Holbrook, Renée Crowther, Ann Lotter, Chiachen Cheng, Derek King
CMAJ Jan 2000, 162 (2) 225-233;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Meta-analysis of benzodiazepine use in the treatment of insomnia
Anne M. Holbrook, Renée Crowther, Ann Lotter, Chiachen Cheng, Derek King
CMAJ Jan 2000, 162 (2) 225-233;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Conclusions
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Psychiatric Medication Users by Age and Sex in the United States, 1999-2018
  • Advise non-pharmacological therapy as first line treatment for chronic insomnia
  • Deprescription des agonistes des recepteurs des benzodiazepines: Lignes directrices de pratique clinique fondees sur les donnees probantes
  • Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline
  • Association between sleep disorders and injury: a nationwide population-based retrospective cohort study
  • Aller au fond des choses: Role des anticholinergiques et des benzodiazepines dans le declin cognitif et les chutes
  • Turning over the rocks: Role of anticholinergics and benzodiazepines in cognitive decline and falls
  • Reducing fall risk while managing hypotension, pain, and poor sleep in an 83-year-old woman
  • Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration
  • Acceptability of Behavioral Treatments for Insomnia
  • Barriers to nonpharmacologic treatments for stress, anxiety, and insomnia: Family physicians' attitudes toward benzodiazepine prescribing
  • Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care
  • Diagnosis and treatment of insomnia
  • Response
  • Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
  • Incidence of Cancer in Individuals Receiving Chronic Zopiclone or Eszopiclone Requires Prospective Study
  • What's wrong with prescribing hypnotics?
  • Treating insomnia
  • Withdrawal of benzodiazepines in elderly long term users does not produce significant adverse effects in the short term
  • Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial
  • Insomnia in the Context of Cancer: A Review of a Neglected Problem
  • Treatment of primary insomnia
  • Treatment of primary insomnia
  • Review: benzodiazepines increase sleep duration but also lead to adverse effects in adults with insomnia
  • The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach
  • Google Scholar

More in this TOC Section

  • Pharmacologic prevention of migraine
  • Diagnosis and acute management of migraine
  • Transient ischemic attack and minor stroke: diagnosis, risk stratification and management
Show more Review

Similar Articles

Collections

  • Topics
    • Drugs: psychotherapeutic
    • Sleep medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire